Axon Enterprise (NASDAQ:AXON) PT Raised to $370.00

Axon Enterprise (NASDAQ:AXON) had its price target boosted by research analysts at Craig Hallum from $325.00 to $370.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Craig Hallum’s price objective suggests a potential upside of 18.64% from the stock’s current price.

A number of other research analysts also recently weighed in on AXON. TheStreet downgraded Axon Enterprise from a “b” rating to a “c+” rating in a report on Tuesday, February 27th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. StockNews.com downgraded Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. The Goldman Sachs Group upped their target price on Axon Enterprise from $297.00 to $339.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Finally, Morgan Stanley upped their target price on Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $333.08.

Axon Enterprise Stock Down 0.3 %

Shares of NASDAQ:AXON opened at $311.86 on Tuesday. Axon Enterprise has a 1 year low of $175.37 and a 1 year high of $329.87. The company has a market cap of $23.53 billion, a PE ratio of 135.59 and a beta of 0.91. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. The stock’s 50-day moving average is $310.82 and its 200 day moving average is $267.44.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, May 6th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. The company had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. During the same quarter in the previous year, the business earned $0.51 EPS. Axon Enterprise’s revenue was up 34.3% compared to the same quarter last year. Sell-side analysts anticipate that Axon Enterprise will post 2.44 EPS for the current year.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. ICA Group Wealth Management LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at $26,000. Trivant Custom Portfolio Group LLC bought a new position in shares of Axon Enterprise during the first quarter valued at $31,000. BKM Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the fourth quarter valued at $32,000. First PREMIER Bank bought a new stake in Axon Enterprise in the 1st quarter worth about $33,000. Finally, Key Financial Inc raised its position in Axon Enterprise by 367.6% in the 4th quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock worth $41,000 after buying an additional 125 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.